Sign in

You're signed outSign in or to get full access.

Drew Ranieri

Managing Director and Senior Equity Research Analyst at TD Cowen

Drew Ranieri is a Managing Director and Senior Equity Research Analyst at TD Cowen, specializing in medtech with a focus on orthopedics, robotics, and insulin delivery systems under the 'Bones, Bots and No More Shots' portfolio. He covers specific companies including SI-BONE, Zimmer Biomet, Intuitive Surgical, and Tandem Diabetes, issuing Buy ratings and price targets such as $109 for Zimmer Biomet, $660 for Intuitive Surgical, and $25 for Tandem Diabetes, while contributing to top medtech stock picks. Ranieri joined TD Cowen as part of its expanded MedTech coverage rollout in early 2026, following prior roles at Morgan Stanley where he served as an Equity Analyst since 2020 and actively participated in earnings calls for companies like Zimmer Biomet and Stryker. He holds FINRA registrations as a broker at TD Securities (USA) LLC, enabling his equity research activities.

Drew Ranieri's questions to STRYKER (SYK) leadership

Question · Q4 2025

Drew Ranieri asked about the implications of Stryker's specialized Breast Care sales force for the Endoscopy business, specifically whether it will drive more product through the installed base or increase utilization. He also inquired about Stryker's CapEx expectations for 2026, given that it was flat year-over-year.

Answer

Kevin Lobo, Chair and CEO, Stryker, explained that the Breast Care sales force, within Endoscopy, was created by combining acquired and internal products, leading to successful expansion and potential for further acquisitions and specialized salespeople. Preston Wells, CFO, Stryker, stated that CapEx focus remains on supporting growth (plants, IT systems) with no change in approach, and the company is also working to improve working capital for greater flexibility.

Ask follow-up questions

Fintool

Fintool can predict STRYKER logo SYK's earnings beat/miss a week before the call

Question · Q4 2025

Drew Ranieri asked about the breast care opportunity within the endoscopy business, now that Stryker has a specialized sales force, and what this means for expanding within the installed base or driving utilization. He also inquired about expectations for CapEx in 2026, following strong free cash flow growth.

Answer

Chair and CEO Kevin Lobo explained that the breast care sales force within endoscopy was created by combining acquired products (MOLLI, NOVADAQ, Invuity) and internal products, leading to a successful first year. He noted this strategy of creating specialized sales forces from tuck-in acquisitions is a core part of Stryker's growth offense. CFO Preston Wells reiterated the target of 70-80% free cash flow conversion, balancing investment with productivity, and stated that CapEx focuses on supporting growth in plants and IT systems, with no change in the overall approach.

Ask follow-up questions

Fintool

Fintool can write a report on STRYKER logo SYK's next earnings in your company's style and formatting